Search

everythinglearnresearchcommunity

for

Search:↓

Most patients with alopecia areata see significant hair regrowth within 93 days of starting ritlecitinib treatment.

Dermoscopy shows that diffuse alopecia areata progresses through specific hair growth stages.

Ritlecitinib improves hair regrowth in alopecia areata over 24 months.

Classic PDRN improves wound healing quality by enhancing cell migration.

A new staining method helps tell growing from resting hairs to diagnose hair loss.

Diazoxide applied to the skin can increase hair growth without harmful side effects.

Oral 5-alpha reductase inhibitors do not increase breast cancer or benign breast disorder risk in women.

SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.

JAK inhibitors helped treat hair loss in two people with Down syndrome.

5 alpha reductase inhibitors can cause sexual, cognitive, and muscle side effects, and may slightly increase aggressive cancer risk.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

After chemotherapy for early breast cancer, 33.4% of patients had long-term significant hair loss, with some hair regrowth over time, but treatments for hair loss were largely ineffective.

The AIRE gene variant rs2075876 is linked to a higher risk of alopecia areata in males.

Topical squaric acid dibutylester worsened discoid lupus erythematosus in a patient.

DHEA improved brain function and behavior in old monkeys and had additional health benefits.

Dutasteride can stabilize hair loss in patients with frontal fibrosing alopecia, but its safety in women is unclear, so use it with caution.

A child with a rare type of rickets showed some improvement with high doses of vitamin D, but such conditions often respond poorly to treatment.

Diphenylcyclopropenone is effective and safe for treating severe alopecia areata in children, with maintenance therapy reducing relapse risk.

Topical DPCP is somewhat effective for hair loss in alopecia areata, but more research is needed.

Measuring minimal residual disease on day 15 helps identify high-risk leukemia patients.

iEdgePathDDA effectively finds new drug-disease links, outperforming other methods.

Adults with alopecia areata stick to their medication better than those with atopic dermatitis.

Carbon dots show promise for tissue repair and growth but need more research to solve current challenges.

CD8+ T cells expand significantly in alopecia areata, suggesting new treatment targets.

The conclusion is that a treatment called cp-asiAR can reduce hair loss and promote hair growth, making it a potential new therapy for androgenetic alopecia.

Both ASR I and ASR II are effective scalp reduction techniques, with ASR I creating finer scars and ASR II removing more bald area and reducing stretch-back.